Ondine To Form Chronic Sinusitis Treatment Subsidiary

Ondine Biopharma Corporation (the "Company" or "Ondine") (TSX:OBP)(AIM:OBP) a
medical technology company developing photodisinfection based products, today
announced its intention to establish a wholly owned subsidiary, "Sinuwave
Technologies Corporation", dedicated to the development and commercialization of
photodisinfection based products that address the chronic sinusitis market. The
subsidiary will license all relevant Ondine intellectual property and know-how
for this application, including technology internally developed over the past
ten years and technology obtained in Ondine's December 2009 acquisition of
Advanced Photodynamic Technologies Inc. ("APT"). Sinuwave Technologies will
leverage the product development, clinical and regulatory experiences of both
the Ondine and APT teams.


"We believe the powerful antimicrobial and anti-inflammatory benefits of
Ondine's photodisinfection technology have the potential to provide substantial
relief to persons who suffer from chronic sinusitis," says Carolyn Cross,
Chairman & CEO of Ondine Biopharma Corporation. "Over 43 million people in North
America suffer from sinusitis. There are over 450,000 patients for whom sinus
surgeries and antibiotics have been unsuccessful. We believe that we can apply
our expertise as global leaders in photodisinfection to address this large unmet
patient need."


About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad
spectrum of bacterial, fungal and viral infections. The Company is focused on
developing leading edge products utilizing its patented light-activated
technology. Photodisinfection provides broad-spectrum antimicrobial efficacy
without encouraging the formation and spread of antibiotic resistance. The
Company is based in Vancouver, British Columbia, Canada, with a research and
development laboratory in Bothell, Washington, USA.


For additional information, please visit www.ondinebiopharma.com and
www.sinuwave.com.


Forward-Looking Statements:

Certain statements contained in this release containing words like "believe",
"intend", "may", "expect" and other similar expressions, are forward-looking
statements that involve a number of risks and uncertainties. Factors that could
cause actual results to differ materially from those projected in the Company's
forward-looking statements include the following: market acceptance of our
technologies and products; our ability to obtain financing; our financial and
technical resources relative to those of our competitors; our ability to keep up
with rapid technological change; government regulation of our technologies; our
ability to enforce our intellectual property rights and protect our proprietary
technologies; the ability to obtain and develop partnership opportunities; the
timing of commercial product launches; the ability to achieve key technical
milestones in key products and other risk factors identified from time to time
in the Company's public filings.